![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 46, 32535-32538, November 12, 1999
§¶,
, and
§¶**
From the Laboratories of Mutations in the two presenilin genes
(PS1, PS2) account for the majority of
early-onset familial Alzheimer's disease (FAD) cases. Converging
evidence from a variety of experimental systems, including fibroblasts
from FAD patients and transgenic animals, indicates that
PS1 mutations modulate intracellular calcium signaling pathways. Despite the potential relevance of these changes to the
pathogenesis of FAD, a comparable effect for PS2 has not
yet been demonstrated experimentally. We examined the effects of
wild-type PS2, and both of the identified FAD mutations in
PS2, on intracellular calcium signaling in
Xenopus oocytes. Inositol 1,4,5-trisphosphate (IP3)-evoked calcium signals were significantly potentiated
in cells expressing either of the PS2 mutations relative to
wild-type PS2-expressing cells and controls. Decay rates of
calcium signals were also significantly accelerated in mutant
PS2-expressing cells in a manner dependent upon
IP3 concentration. The finding that mutations in both
PS1 and PS2 modulate intracellular calcium
signaling suggests that these disturbances may represent a common
pathogenic mechanism of presenilin-associated FAD.
Most cases of familial Alzheimer's disease
(FAD)1 are linked to
mutations in two related genes, presenilin-1 and
presenilin-2 (PS1, PS2) (1). These
genes, which diverged from a single ancestor, share a similar genomic
organization and encode proteins that are 67% identical. PS1 and PS2
are multipass, integral membrane proteins localized predominantly to
the endoplasmic reticulum (ER) (2, 3) and are widely expressed
throughout the brain (4). Despite their similarities, there are genetic
and physiological differences between these two molecules that may
reflect important functional differences. For instance, while over 50 mutations have been identified in PS1, only two mutations
have been found in PS2 that are definitively linked to FAD:
one in a group of eight Volga German kindreds (PS2N141I) and
another in an Italian kindred (PS2M239V) (5, 6). In
addition, PS1 mutations cause an aggressive form of FAD with
a particularly early age of onset, whereas PS2 is associated
with a form of FAD that more closely resembles sporadic AD in terms of
age of onset and disease duration (7). Physiologically, although PS1
and PS2 share in common certain features such as modulating A PS1 mutations alter intracellular calcium signaling pathways
in a variety of experimental systems (10, 12-19). These changes may be
highly relevant to the pathogenesis of AD, since calcium dysregulation
can contribute to several key features of AD, including increased A Circumstantial experimental evidence supports the potential involvement
of PS2 in intracellular calcium regulation. For instance, PS2 interacts
with a calcium-binding protein, calsenilin, that has been shown to
regulate the levels of the caspase-3 cleavage product of PS2 (25).
Although the function of calsenilin remains to be determined, sequence
homology with neuronal calcium sensor-1 suggests that it may play a
role in regulating intracellular calcium levels. Moreover, PS2, but not
PS1, interacts with another calcium-binding protein known as sorcin
(26). Sorcin is known to modulate the activity of ryanodine receptors
(27), a major type of intracellular calcium release channel, and has
also been found to associate with L-type voltage-gated
calcium channels (28). Collectively, these findings suggest a possible
physiological role for PS2 in regulating calcium signaling pathways, a
function that may be modulated by FAD mutations.
Here we studied the effects of wild-type PS2
(wtPS2) and both of the identified FAD-linked PS2
mutations on calcium signaling in Xenopus oocytes. We show
that, relative to controls, both FAD mutations in PS2
significantly potentiated calcium signals evoked by the ubiquitous
intracellular second messenger inositol 1,4,5-trisphosphate (IP3). Notably, both PS2 mutations also
significantly accelerated decay rates of calcium signals evoked by high
levels of IP3. These findings lend strong support to the
hypothesis that alterations in calcium signaling pathways may be a
common pathogenic mechanism by which presenilin mutations contribute to
FAD.
cRNA Synthesis and Injection--
Full-length cDNAs encoding
human wtPS2, PS2NI141I, and PS2M239V
were the generous gift of Dr. John Hardy. Synthesis of
m7G(5')ppp(5')G-capped cRNA was performed by run-off
transcription of template plasmids linearized with the restriction
endonuclease XbaI using the Riboprobe Gemini System
(Promega) according to manufacturer's recommendations. The quantity
and quality of the resulting transcripts were determined by
spectrophotometric analysis and direct visualization on a denaturing
gel as described elsewhere (17). Stage V and VI oocytes of
Xenopus laevis (Xenopus I, Ann Arbor, MI) were
defolliculated by two 1-h treatments with 0.5 mg/ml collagenase and
were injected the following day with 46 nl of the appropriate cRNA (500 ng/µl) or RNase-free H2O (17).
Injection with Calcium Indicator and Caged
IP3--
Three days after cRNA injection and 1-4 h
prior to calcium imaging experiments, oocytes were loaded
with 46 nl of a mixture containing 0.25 mM caged
IP3 (c-IP3;
D-myo-inositol 1,4,5-trisphosphate, P4(5)-(1-(2-nitrophenyl)ethyl) ester; Molecular
Probes, Eugene, OR) and 1 mM of the low affinity calcium
indicator Oregon Green-5N (OG-5N; Molecular Probes), yielding final
concentrations in the oocytes of ~12 and ~46 µM,
respectively. To ensure equal loading of the oocytes, we used a
piston-driven Nanoject microinjector apparatus (Drummond Scientific)
fitted with freshly pulled glass electrodes with tip diameters of
~15-20 µm.
Photolysis of c-IP3 and Calcium
Imaging--
Photolysis of c-IP3 to liberate free
intracellular IP3 was achieved using flashes of UV light
(340-400 nm) derived from a mercury arc lamp (17). The concentration
of IP3 photoreleased by UV light is a function of both
flash duration, controlled by a mechanical shutter, and flash
intensity, controlled by a neutral density filter (29). For experiments
using supramaximal IP3 stimulation, the neutral density
filter was reduced so that further increases in UV intensity failed to
generate increased calcium signals in response to a fixed (200 ms)
flash duration. Remaining experiments used a neutral density setting
giving a flash intensity ~57-fold weaker. Estimates of
IP3 concentrations (see legend to Fig. 2) were calculated
based on previous findings indicating that ~50 nM
IP3 is required to initiate a calcium wave (29).
Calcium-dependent fluorescence changes of OG-5N in response
to photoreleased IP3 were imaged using a custom-built
line-scanning confocal microscope, and data were recorded and analyzed
as described previously (30). Fluorescence intensities were averaged
over a 50-µm scan line and are expressed as the change in intensity over the basal level of fluorescence prior to stimulation
( Western Blotting--
Immediately following completion of the
calcium imaging experiments, cells were frozen for later processing.
Protein extracts were prepared as described previously (17) and
concentrations determined by the Bradford method. Equal amounts of
protein (10 µg) were separated by SDS-polyacrylamide gel
electrophoresis on 5 or 10% acrylamide gels, transferred to
nitrocellulose membranes, blocked overnight in 5% non-fat milk in
Tris-buffered saline (pH 7.5) supplemented with 0.2% Tween 20, and
processed as described previously (17). The IP3-mediated Calcium Release Is Potentiated by PS2
Mutations--
To determine whether PS2 mutations modulate
IP3-mediated calcium signaling, we conducted fluorescent
calcium imaging in Xenopus oocytes expressing wild-type or
mutant PS2 and H2O-injected controls (Fig.
1). Intracellular IP3 was
liberated from a caged precursor by flashes of UV light. By varying the
flash durations, different relative amounts of IP3 could be
photoreleased in a reproducible manner. The rapid calcium signals
evoked by photorelease of caged IP3 are almost exclusively
due to liberation of calcium from the ER through IP3
receptors and negligible amounts of calcium influx from outside the
cell occur at this time scale (33).
Relative to controls, cells expressing either PS2N141I or
PS2M239V exhibited larger mean peak responses for each flash
duration tested, whereas wtPS2-expressing cells produced
responses intermediate between mutant-expressing and control cells
(Fig. 1, A and B). Moreover, with increasing
flash duration, mean peak calcium responses approached higher
asymptotic maxima in mutant PS2-expressing cells relative to
controls (e.g. for 120-ms flashes,
The threshold for IP3-mediated calcium release was lower in
cells expressing PS2 mutations relative to controls, since
we found that mutant-expressing cells responded more frequently than controls to the lowest flash durations tested. For example, in response
to flash durations of 20 ms, six out of nine cells expressing PS2N141I responded as compared with only 1 of 10 H2O-injected controls (p < 0.001 by
PS2 Mutations Accelerate Decay Rates of Calcium Signals--
We
also examined the effects of PS2 mutations on the decay
rates of calcium signals evoked by different concentrations of IP3, which were quantitated by measuring the half-decay
time (t1/2) of individual signals (Fig.
2). At low [IP3] (~0.15
µM; see "Experimental Procedures"),
calcium responses in wild-type and mutant PS2-expressing cells and controls decayed at similar rates (Fig. 2, A and
B). By comparison, following supramaximal IP3
stimulation ("high [IP3]"; ~30 µM),
decay rates were significantly slowed in wtPS2-expressing cells and controls (which were not significantly different from each
other; Fig. 2, C and D). In striking contrast,
decay rates were significantly accelerated in mutant
PS2-expressing cells following supramaximal IP3
stimulation relative to wtPS2-expressing cells and
controls (Fig. 2, C and D; see also bold
traces in Fig. 1A).
Expression of PS2 and IP3 Receptor Proteins--
To
ascertain if differences in calcium signaling were due to differences
in PS2 expression levels, protein extracts from the oocytes used for
calcium imaging experiments were subjected to Western analysis using
several anti-PS2 antibodies (Fig.
3A). For each antibody tested,
protein expression levels did not differ by more than 5% among the
PS2 cRNA-injected conditions, as determined by densitometric
analysis. Therefore, the increased potentiation observed in mutant
PS2-expressing cells relative to wild-type PS2-expressing cells is not
attributable to differences in protein expression levels.
Interestingly, some antibodies, including the
To address the mechanism by which PS2 mutations potentiate
IP3-mediated calcium release, we also conducted a Western
analysis of type-I IP3 receptors (Fig. 3B),
which are the only type of calcium release channel expressed in
Xenopus oocytes (35). IP3 receptor protein
levels differed only slightly (~7%) between control cells and cells
expressing wild-type or mutant PS2, and these small differences did not
correlate consistently with the amplitudes of calcium responses in the
various conditions. These findings indicate that mechanisms other than
IP3 receptor up-regulation are responsible for the observed
potentiation in IP3-mediated calcium signaling.
The "calcium hypothesis" of AD proposes that perturbed
intracellular calcium homeostasis plays a central role in AD
neurodegeneration (36). In support of the idea, several distinct
AD-linked PS1 mutations have been shown to modulate calcium
signaling in a variety of systems, including fibroblasts from FAD
patients (12, 15, 16), mutant PS1 "knock-in" mice (18),
transgenic mice (19), transfected PC-12 cells (10, 14), and
Xenopus oocytes (17). However, to our knowledge, the effects
of PS2 mutations on calcium signaling have not previously
been examined. We addressed this question by measuring
IP3-mediated calcium signals in Xenopus oocytes
expressing wild-type PS2 and the two identified FAD-linked mutations in PS2. Calcium signals were potentiated in
oocytes overexpressing wild-type PS2 as compared with
H2O-injected controls, and a further potentiation was
observed in oocytes expressing similar amounts of mutant
PS2. Notably, the nature and extent of this potentiation
closely resembles the results we observed for mutant PS1
using identical methods in the same system (17). Therefore, FAD
mutations in both PS1 and PS2 lead to similar
alterations in IP3-mediated calcium signaling, providing
further evidence that intracellular calcium dysregulation may represent
a common pathophysiological consequence of all AD-linked presenilin
mutations. Since elevated cytosolic calcium levels can lead to several
hallmark features of AD, including increased levels of A Oocytes expressing wild-type PS2 exhibited potentiated
IP3-mediated calcium release relative to
H2O-injected controls, albeit to a lesser extent than those
expressing the FAD mutations. Overexpression of wild-type
PS1 in the same system also produced a comparable potentiation in IP3-mediated calcium release (17). Although the significance of these findings is not presently clear, these results may reflect a physiological function of endogenous presenilins in calcium signaling, a function that is perturbed by FAD mutations. Given the interaction of the presenilins with calsenilin (25), which is
homologous to proteins involved in calcium homeostasis, and sorcin,
which modulates calcium release through ryanodine receptors, this
possibility warrants further investigation.
Although the mechanism by which PS2 mutations potentiate
IP3-mediated calcium signaling remains to be established,
up-regulation of IP3 receptors does not appear to be
involved, since comparable levels of IP3 receptor levels
were present in control cells and in cells expressing wild-type and
mutant PS2. Alternative possibilities may involve alteration
of IP3-receptor function or overfilling of the ER calcium
pools. In support of the latter idea, measurements of store content
obtained by using thapsigargin to release calcium show an enhancement
in PC-12 cells expressing mutant PS1 (14).
Rates of decay of calcium signals evoked by supramaximal
[IP3] were also markedly accelerated by PS2
mutations. The decay of the fluorescent calcium signal represents a
balance between calcium efflux through activated IP3
receptors and mechanisms that remove calcium ions from the cytosol
(e.g. reuptake into the ER, uptake into mitochondria,
extrusion across plasma membrane). Although we cannot entirely exclude
effects of PS2 mutations on calcium sequestration
mechanisms, it seems unlikely that this could result in an acceleration
of calcium transport at high, but not low, [IP3]. One
mechanism that may account for these results might be an increase in
the rate of inactivation of IP3 receptors in the presence
of high [IP3]. Alternatively, the accelerated decay rates
might be due to the increased calcium release evoked by high
[IP3] in the mutant PS2-expressing cells,
since it is known that high local levels of cytosolic calcium can
actually inhibit the opening of IP3 receptors (37).
The fact that intracellular calcium signaling is modulated by mutations
in both PS1 and PS2 increases support for the
hypothesis that these disturbances play a causative role in the
pathogenesis of FAD. In view of the central importance of intracellular
calcium regulation for numerous cellular processes, elucidation of the mechanisms responsible for these changes is clearly warranted and could
uncover novel targets for therapeutic intervention.
We thank Drs. Carl Cotman, Christian Haass,
and Gopal Thinakaran for providing us with PS2 antibodies, Dr. John
Hardy for the PS2 cDNAs, Alan Dakak for technical assistance, and
Drs. Nicholas Callamaras and Jonathan Marchant for technical advice.
*
This work was supported by a grant from the University of
California Irvine-Markey Program in Human Neurobiology (to F. M. L.), Grant GM-48071 (to I. P.), and a scholarship from the
Glenn Foundation/American Federation for Aging Research (awarded to M. A. L.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
**
To whom correspondence should be addressed: Dept. of Neurobiology & Behavior, University of California, Irvine, 1109 Gillespie Neuroscience
Facility, Irvine, CA 92697-4545. Tel.: 949-824-1232; Fax: 949-824-7356;
E-mail: laferla@uci.edu.
The abbreviations used are:
FAD, familial
Alzheimer's disease;
AD, Alzheimer's disease;
c-IP3, caged IP3;
ER, endoplasmic reticulum;
IP3, inositol 1,4,5-trisphosphate;
PS1 and PS2, presenilin-1 and
presenilin-2;
OG-5N, Oregon green-5N.
Molecular Neuropathogenesis
and
Cellular and Molecular Neurobiology,
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
production, there are also key distinctions. Regarding their effect on
apoptosis, for example, wild-type PS2 (wtPS2), but not PS1, has been
shown to be proapoptotic (8-10). In addition, PS1 and PS2 exhibit
contrasting roles in affecting neuronal differentiation in
vitro (11). Therefore, the functions mediated by the presenilins
cannot be assumed to be identical.
production (20, 21), hyperphosphorylation of tau (22), enhanced
vulnerability to cell death (10, 23), and even memory-related deficits
(24). However, despite the likely significance of these changes to the
pathogenesis of AD, no studies have yet reported the effects of
PS2 mutations on calcium signaling.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
F/Fo). Statistical comparisons were
made using two-factor analysis of variance with replication. All
results are presented as mean values ± S.E.
PS2N
antibody (the generous gift of Dr. Carl Cotman) was generated in
rabbits by immunization with a synthetic peptide corresponding to amino
acids 8-21 of the PS2 protein, affinity-purified, and used at a
dilution of 1:1000. Other antibodies and dilutions used in this study
include PS2NT (1:5000; the generous gift of Dr. Gopal
Thinakaran; Ref. 31); PS2 loop antibody 3711 (1:500; the generous gift
of Dr. Christian Haass; Ref. 32); and
IP3R-I, a rabbit
polyclonal anti-type-I IP3 receptor antibody (Affinity
Bioreagents, Golden, CO). Quantitative densitometric analyses were
performed on digitized images of immunoblots using the Stratagene
EagleEye II gel documentation system according to manufacturer's
recommendations (Stratagene, La Jolla, CA).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (29K):
[in a new window]
Fig. 1.
PS2 mutations potentiate
IP3-evoked calcium liberation. A, sample
recordings of calcium-dependent OG-5N fluorescence changes
evoked by photoreleased IP3 in single oocytes injected 3 days prior to recording with either H2O or 25 ng of cRNA
encoding either wtPS2, PS2N141I, or
PS2M239. Superimposed traces show responses evoked by 20-, 60-, and 120-ms flash durations, expressed as the change in
fluorescence intensity relative to baseline
(
F/Fo). Arrowheads indicate
approximate time of flash onset. Note that responses elicited by 120-ms
flashes (bold) are markedly accelerated in mutant
PS2-expressing cells, but not in wtPS2-expressing
cells or controls, relative to signals evoked by shorter flash
durations. B, mean peak
F/Fo plotted as a function of flash
duration (i.e. [IP3]) in control cells (
),
or cells expressing wtPS2 (
), PS2N141I (
),
or PS2M239V (
) (n = 8-10 oocytes per
condition taken from a single donor frog). C, quantitative
comparison of mean peak
F/Fo in
response to maximal IP3 stimulation in cells expressing
each of the PS2 constructs or controls (n = 28-30 cells per condition from two donor frogs). All values represent
means ± S.E., although S.E. values were omitted where data were
not normally distributed; *, p < 0.05 relative to
H2O-injected controls; **, p < 0.001 relative to H2O-injected controls and p < 0.05 relative to wtPS2-expressing cells.
F/Fo = 1.40 ± 0.08 versus 0.93 ± 0.06 for PS2N141I-injected
cells versus controls, respectively; p < 0.001; Fig. 1B). To ensure that absolute maximal levels of
IP3-mediated calcium release had been achieved, cells were
further stimulated with supramaximal [IP3] (~30
µM; see "Experimental Procedures"). As
with lower stimulus intensities, mean peak calcium responses following
supramaximal IP3 stimulation were significantly increased
in cells expressing PS2 mutations relative both to
wtPS2-expressing cells and to controls (Fig. 1C).
Therefore, PS2 mutations consistently increase the mean
amplitude of calcium responses evoked by a wide range of
IP3 levels.
2 analysis). PS2M239V-expressing cells
displayed even more marked differences, being the only cells to respond
to flash durations of 10 ms (2 out of 10 trials; see Fig.
1B). Taken together, these data suggest that PS2
mutations confer an increased sensitivity to IP3.

View larger version (31K):
[in a new window]
Fig. 2.
PS2 mutations accelerate decay rates of
calcium signals evoked by high, but not low, [IP3].
A and C, average calcium responses evoked by
"low [IP3]" (A; ~0.15 µM)
or "high [IP3]" (C; ~30
µM) in cells expressing either wtPS2,
PS2N141I, or PS2M239V. Traces represent the
averages of 10 responses per condition, that have been normalized and
superimposed for comparison. B and D,
quantitation of mean times to decay from peak
F/Fo to one-half peak
(t1/2) for all recordings (n = 28-30 per condition) following stimulation with low or high
[IP3], respectively. Note that decay rates of calcium
signals in mutant PS2-expressing cells are accelerated at
high, but not low, [IP3]; wtPS2-expressing
cells did not differ significantly from controls. *, p < 0.05 relative to H2O-injected controls; **,
p < 0.001 relative to H2O-injected
controls and p < 0.05 relative to
PS2N141I-expressing cells.
PS2N
antibody (Fig. 3A), also detected a weak band in the
H2O-injected controls, presumably reflecting endogenous
Xenopus presenilin (34).

View larger version (42K):
[in a new window]
Fig. 3.
Potentiation of calcium signaling is not
attributable to differences in PS2 or IP3 receptor protein
expression levels. Immunoblots of protein extracts from control
cells and cells injected with wtPS2 or PS2N141I
or PS2M239V cRNA. A, representative immunoblot of
PS2 protein levels using antibody
PS2N: levels of PS2
protein did not differ by more than 5% as determined by densitometric
analysis. Similar results were obtained using several other well
characterized anti-PS2 antibodies (see "Experimental Procedures").
Note the presence of a faint band in the H2O-injected cells
which may represent Xenopus presenilin. B, levels
of type-I IP3 receptors detected with antibody
IP3R-I (Affinity Bioreagents). Protein levels differed
only slightly (<7%), and these differences do not correlate with
differences in mean amplitudes of calcium signals exhibited by cells in
the various conditions.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
(20, 21), hyperphosphorylated tau (22), and enhanced susceptibility to cell death
(10, 23), these findings lend additional support to the hypothesis that
calcium dysregulation plays a causative role in the pathogenesis of AD.
Conversely, our data do not reveal differences in
IP3-mediated calcium signaling that may account for the
contrasting functional differences between the PS1 and PS2 proteins.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Cruts, M.,
van Duijn, C. M.,
Backhovens, H.,
Van den Broeck, M.,
Wehnert, A.,
Serneels, S.,
Sherrington, R.,
Hutton, M.,
Hardy, J.,
St George-Hyslop, P. H.,
Hofman, A.,
and Van Broeckhoven, C.
(1998)
Hum. Mol. Genet.
7,
43-51 2.
Kovacs, D. M.,
Fausett, H. J.,
Page, K. J.,
Kim, T. W.,
Moir, R. D.,
Merriam, D. E.,
Hollister, R. D.,
Hallmark, O. G.,
Mancini, R.,
Felsenstein, K. M.,
Hyman, B. T.,
Tanzi, R. E.,
and Wasco, W.
(1996)
Nat. Med.
2,
224-229[CrossRef][Medline]
[Order article via Infotrieve]
3.
Zhang, J.,
Kang, D. E.,
Xia, W.,
Okochi, M.,
Mori, H.,
Selkoe, D. J.,
and Koo, E. H.
(1998)
J. Biol. Chem.
273,
12436-12442 4.
Cribbs, D. H.,
Chen, L. S.,
Bende, S. M.,
and LaFerla, F. M.
(1996)
Am. J. Pathol.
148,
1797-1806[Abstract]
5.
Levy-Lahad, E.,
Wasco, W.,
Poorkaj, P.,
Romano, D. M.,
Oshima, J.,
Pettingell, W. H., Yu, C. E.,
Jondro, P. D.,
Schmidt, S. D.,
Wang, K.,
et al..
(1995)
Science
269,
973-977 6.
Rogaev, E. I.,
Sherrington, R.,
Rogaeva, E. A.,
Levesque, G.,
Ikeda, M.,
Liang, Y.,
Chi, H.,
Lin, C.,
Holman, K.,
Tsuda, T.,
et al..
(1995)
Nature
376,
775-778[CrossRef][Medline]
[Order article via Infotrieve]
7.
Renbaum, P.,
and Levy-Lahad, E.
(1998)
Cell. Mol. Life Sci.
54,
910-919[CrossRef][Medline]
[Order article via Infotrieve]
8.
Vito, P.,
Wolozin, B.,
Ganjei, J. K.,
Iwasaki, K.,
Lacana, E.,
and D'Adamio, L.
(1996)
J. Biol. Chem.
271,
31025-31028 9.
Deng, G.,
Pike, C. J.,
and Cotman, C. W.
(1996)
FEBS Lett
397,
50-54[CrossRef][Medline]
[Order article via Infotrieve]
10.
Guo, Q.,
Sopher, B. L.,
Furukawa, K.,
Pham, D. G.,
Robinson, N.,
Martin, G. M.,
and Mattson, M. P.
(1997)
J. Neurosci.
17,
4212-4222 11.
Hong, C. S.,
Caromile, L.,
Nomata, Y.,
Mori, H.,
Bredesen, D. E.,
and Koo, E. H.
(1999)
J. Neurosci.
19,
637-643 12.
Ito, E.,
Oka, K.,
Etcheberrigaray, R.,
Nelson, T. J.,
McPhie, D. L.,
Tofel-Grehl, B.,
Gibson, G. E.,
and Alkon, D. L.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
534-538 13.
Gibson, G. E.,
Zhang, H.,
Toral-Barza, L.,
Szolosi, S.,
and Tofel-Grehl, B.
(1996)
Biochim. Biophys. Acta
1316,
71-77[Medline]
[Order article via Infotrieve]
14.
Guo, Q.,
Furukawa, K.,
Sopher, B. L.,
Pham, D. G.,
Xie, J.,
Robinson, N.,
Martin, G. M.,
and Mattson, M. P.
(1996)
Neuroreport
8,
379-383[Medline]
[Order article via Infotrieve]
15.
Gibson, G. E.,
Vestling, M.,
Zhang, H.,
Szolosi, S.,
Alkon, D.,
Lannfelt, L.,
Gandy, S.,
and Cowburn, R. F.
(1997)
Neurobiol. Aging
18,
573-580[CrossRef][Medline]
[Order article via Infotrieve]
16.
Etcheberrigaray, R.,
Hirashima, N.,
Nee, L.,
Prince, J.,
Govoni, S.,
Racchi, M.,
Tanzi, R. E.,
and Alkon, D. L.
(1998)
Neurobiol. Dis.
5,
37-45[CrossRef][Medline]
[Order article via Infotrieve]
17.
Leissring, M. A.,
Paul, B. A.,
Parker, I.,
Cotman, C. W.,
and LaFerla, F. M.
(1999)
J. Neurochem.
72,
1061-1068[CrossRef][Medline]
[Order article via Infotrieve]
18.
Guo, Q.,
Fu, W.,
Sopher, B. L.,
Miller, M. W.,
Ware, C. B.,
Martin, G. M.,
and Mattson, M. P.
(1999)
Nat. Med.
5,
101-106[CrossRef][Medline]
[Order article via Infotrieve]
19.
Begley, J. G.,
Duan, W.,
Chan, S.,
Duff, K.,
and Mattson, M. P.
(1999)
J. Neurochem.
72,
1030-1039[CrossRef][Medline]
[Order article via Infotrieve]
20.
Querfurth, H. W.,
and Selkoe, D. J.
(1994)
Biochemistry
33,
4550-4561[CrossRef][Medline]
[Order article via Infotrieve]
21.
Querfurth, H. W.,
Jiang, J.,
Geiger, J. D.,
and Selkoe, D. J.
(1997)
J. Neurochem.
69,
1580-1591[Medline]
[Order article via Infotrieve]
22.
Mattson, M. P.,
Engle, M. G.,
and Rychlik, B.
(1991)
Mol. Chem. Neuropathol.
15,
117-142[Medline]
[Order article via Infotrieve]
23.
Mattson, M. P.,
Guo, Q.,
Furukawa, K.,
and Pedersen, W. A.
(1998)
J. Neurochem.
70,
1-14[Medline]
[Order article via Infotrieve]
24.
Disterhoft, J. F.,
Moyer, J. R., Jr.,
and Thompson, L. T.
(1994)
Ann. N. Y. Acad. Sci.
747,
382-406[Medline]
[Order article via Infotrieve]
25.
Buxbaum, J. D.,
Choi, E. K.,
Luo, Y.,
Lilliehook, C.,
Crowley, A. C.,
Merriam, D. E.,
and Wasco, W.
(1998)
Nat. Med.
4,
1177-1181[CrossRef][Medline]
[Order article via Infotrieve]
26.
Kim, T.-W.,
Pettingell, W. P.,
and Tanzi, R. E.
(1998)
Soc. Neurosci. Abstr.
24,
757
27.
Meyers, M. B.,
Pickel, V. M.,
Sheu, S. S.,
Sharma, V. K.,
Scotto, K. W.,
and Fishman, G. I.
(1995)
J. Biol. Chem.
270,
26411-26418 28.
Meyers, M. B.,
Puri, T. S.,
Chien, A. J.,
Gao, T.,
Hsu, P. H.,
Hosey, M. M.,
and Fishman, G. I.
(1998)
J. Biol. Chem.
273,
18930-18935 29.
Callamaras, N.,
and Parker, I.
(1998)
Methods Enzymol.
291,
380-403[Medline]
[Order article via Infotrieve]
30.
Sun, X. P.,
Callamaras, N.,
Marchant, J. S.,
and Parker, I.
(1998)
J. Physiol. (Lond.)
509,
67-80 31.
Saura, C. A.,
Tomita, T.,
Davenport, F.,
Harris, C. L.,
Iwatsubo, T.,
and Thinakaran, G.
(1999)
J. Biol. Chem.
274,
13818-13823 32.
Walter, J.,
Grunberg, J.,
Schindzielorz, A.,
and Haass, C.
(1998)
Biochemistry
37,
5961-5967[CrossRef][Medline]
[Order article via Infotrieve]
33.
Yao, Y.,
and Parker, I.
(1993)
J. Physiol. (Lond.)
468,
275-295 34.
Tsujimura, A.,
Yasojima, K.,
and Hashimoto-Gotoh, T.
(1997)
Biochem. Biophys. Res. Commun.
231,
392-396[CrossRef][Medline]
[Order article via Infotrieve]
35.
Kume, S.,
Muto, A.,
Aruga, J.,
Nakagawa, T.,
Michikawa, T.,
Furuichi, T.,
Nakade, S.,
Okano, H.,
and Mikoshiba, K.
(1993)
Cell
73,
555-570[CrossRef][Medline]
[Order article via Infotrieve]
36.
Khachaturian, Z. S.
(1987)
Neurobiol. Aging
8,
345-346[CrossRef][Medline]
[Order article via Infotrieve]
37.
Bezprozvanny, I.,
Watras, J.,
and Ehrlich, B. E.
(1991)
Nature
351,
751-754[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
This article has been cited by other articles:
![]() |
Y. S. Oh and R. J. Turner Effect of {gamma}-secretase inhibitors on muscarinic receptor-mediated calcium signaling in human salivary epithelial cells Am J Physiol Cell Physiol, July 1, 2006; 291(1): C76 - C82. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Cook, X. Li, S. D. Cherry, and A. R. Cantrell Presenilin 1 Deficiency Alters the Activity of Voltage-Gated Ca2+ Channels in Cultured Cortical Neurons J Neurophysiol, December 1, 2005; 94(6): 4421 - 4429. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Stutzmann Calcium Dysregulation, IP3 Signaling, and Alzheimer's Disease Neuroscientist, April 1, 2005; 11(2): 110 - 115. [Abstract] [PDF] |
||||
![]() |
C. M. P. Ribeiro, A. M. Paradiso, M. A. Carew, S. B. Shears, and R. C. Boucher Cystic Fibrosis Airway Epithelial Ca2+i Signaling: THE MECHANISM FOR THE LARGER AGONIST-MEDIATED Ca2+i SIGNALS IN HUMAN CYSTIC FIBROSIS AIRWAY EPITHELIA J. Biol. Chem., March 18, 2005; 280(11): 10202 - 10209. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Kitagawa, S. Shimohama, T. Oeda, K. Uemura, R. Kohno, A. Kuzuya, H. Shibasaki, and N. Ishii The Role of the Presenilin-1 Homologue Gene sel-12 of Caenorhabditis elegans in Apoptotic Activities J. Biol. Chem., March 28, 2003; 278(14): 12130 - 12134. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Morohashi, N. Hatano, S. Ohya, R. Takikawa, T. Watabiki, N. Takasugi, Y. Imaizumi, T. Tomita, and T. Iwatsubo Molecular Cloning and Characterization of CALP/KChIP4, a Novel EF-hand Protein Interacting with Presenilin 2 and Voltage-gated Potassium Channel Subunit Kv4 J. Biol. Chem., April 19, 2002; 277(17): 14965 - 14975. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Leissring, M. P. Murphy, T. R. Mead, Y. Akbari, M. C. Sugarman, M. Jannatipour, B. Anliker, U. Muller, P. Saftig, B. De Strooper, et al. A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP PNAS, March 21, 2002; (2002) 72033799. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Mah, G. Perry, M. A. Smith, and M. J. Monteiro Identification of Ubiquilin, a Novel Presenilin Interactor That Increases Presenilin Protein Accumulation J. Cell Biol., November 13, 2000; 151(4): 847 - 862. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Leissring, T. R. Yamasaki, W. Wasco, J. D. Buxbaum, I. Parker, and F. M. LaFerla Calsenilin reverses presenilin-mediated enhancement of calcium signaling PNAS, July 18, 2000; 97(15): 8590 - 8593. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Leissring, Y. Akbari, C. M. Fanger, M. D. Cahalan, M. P. Mattson, and F. M. LaFerla Capacitative Calcium Entry Deficits and Elevated Luminal Calcium Content in Mutant Presenilin-1 Knockin Mice J. Cell Biol., May 15, 2000; 149(4): 793 - 798. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Pack-Chung, M. B. Meyers, W. P. Pettingell, R. D. Moir, A. M. Brownawell, I. Cheng, R. E. Tanzi, and T.-W. Kim Presenilin 2 Interacts with Sorcin, a Modulator of the Ryanodine Receptor J. Biol. Chem., May 5, 2000; 275(19): 14440 - 14445. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Leissring, M. P. Murphy, T. R. Mead, Y. Akbari, M. C. Sugarman, M. Jannatipour, B. Anliker, U. Muller, P. Saftig, B. De Strooper, et al. A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP PNAS, April 2, 2002; 99(7): 4697 - 4702. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |